| Nov 4 |
Castle Biosciences Reports Third Quarter 2024 Results
|
| Nov 3 |
Castle Biosciences Q3 2024 Earnings Preview
|
| Nov 1 |
Castle Biosciences, Inc. (CSTL) Hit a 52 Week High, Can the Run Continue?
|
| Oct 29 |
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
|
| Oct 29 |
Liquidia Technologies, Inc. (LQDA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
|
| Oct 23 |
Here's Why Momentum in Castle Biosciences (CSTL) Should Keep going
|
| Oct 22 |
Castle Biosciences, Inc. (CSTL) is a Great Momentum Stock: Should You Buy?
|
| Oct 20 |
Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
|
| Oct 16 |
Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
|
| Oct 15 |
Castle Biosciences, Inc. (CSTL) Soars to 52-Week High, Time to Cash Out?
|
